The review discusses the effectiveness and side effects of Pirfenidone and Nintedanib, two specific drugs used to treat idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). Both drugs have been shown to slow disease progression and reduce mortality rates, but they also carry significant side effects, particularly gastrointestinal symptoms and photosensitivity. The review highlights the importance of managing these side effects to ensure patient compliance and treatment continuation. It also emphasizes the need for further research to optimize the use of antifibrotic agents, particularly in post-COVID-19 fibrosis and other ILD conditions. The cost-effectiveness of these drugs varies across different countries, and their efficacy in early treatment of progressive fibrosis is still under investigation. The review concludes by emphasizing the ongoing need for research to establish effective treatments for ILD progression and to minimize the impact of the disease on patients' lives.The review discusses the effectiveness and side effects of Pirfenidone and Nintedanib, two specific drugs used to treat idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). Both drugs have been shown to slow disease progression and reduce mortality rates, but they also carry significant side effects, particularly gastrointestinal symptoms and photosensitivity. The review highlights the importance of managing these side effects to ensure patient compliance and treatment continuation. It also emphasizes the need for further research to optimize the use of antifibrotic agents, particularly in post-COVID-19 fibrosis and other ILD conditions. The cost-effectiveness of these drugs varies across different countries, and their efficacy in early treatment of progressive fibrosis is still under investigation. The review concludes by emphasizing the ongoing need for research to establish effective treatments for ILD progression and to minimize the impact of the disease on patients' lives.